Lytix Biopharma's NeoLIPA Treatment Meets Primary Endpoint in Clinical Trial

Lytix Biopharma said its combination therapy NeoLIPA met the primary endpoint in a clinical trial for melanoma. The result marks progress for the company’s oncology pipeline of oncolytic molecule therapies targeting solid tumors. The company has not yet provided further trial details or outlined next development steps.